- WuXi Biologics named constituent of FTSE4Good Index Series for fourth straight year.
- Recognition highlights company’s strong sustainability performance and ESG strategy.
WuXi Biologics (2269.HK), a global Contract Research, Development, and Manufacturing Organization (CRDMO), has been named once again as a constituent of the FTSE4Good Index Series, marking its fourth consecutive year of inclusion. Launched by FTSE Russell, the FTSE4Good Index Series evaluates companies based on their sustainability practices across developed and emerging markets.
The index, comprising over 8,000 securities globally, recognizes companies demonstrating robust environmental, social, and governance (ESG) performance. WuXi Biologics has shown significant improvement in its FTSE Russell ESG score, placing in the top 7% of its industry in 2024.
Dr. Chris Chen, CEO and Chairman of the ESG Committee at WuXi Biologics, expressed pride in the company’s achievement, stating, “We are very proud to be acknowledged again by FTSE Russell as a constituent of the FTSE4Good Index Series. It underscores our firm commitment to sustainability, demonstrating the success of our comprehensive ESG strategy and our effective implementation of ESG approaches.”
Aligned with the United Nations Sustainable Development Goals, WuXi Biologics continues to advance its sustainability agenda, gaining recognition from major ESG rating agencies. The company’s accomplishments include recent additions to the S&P Dow Jones Sustainability™ World Index and Emerging Markets Index, a “AAA” rating from MSCI ESG Ratings, and top accolades from EcoVadis, Sustainalytics, and CDP for water security and climate change initiatives.
Overview of outsourcing trends 
